CA Patent

CA2902071C — Combination chemotherapy regimens using albumin/paclitaxel nanoparticles and nucleoside analogs

Assigned to Abraxis Bioscience LLC · Expires 2019-10-08 · 7y expired

What this patent protects

The present invention provides combination use of nanoparticles comprising paclitaxel and an albumin and gemcitabine or capecitabine for treating solid tumor.

USPTO Abstract

The present invention provides combination use of nanoparticles comprising paclitaxel and an albumin and gemcitabine or capecitabine for treating solid tumor.

Drugs covered by this patent

Patent Metadata

Patent number
CA2902071C
Jurisdiction
CA
Classification
—
Expires
2019-10-08
Drug substance claim
No
Drug product claim
No
Assignee
Abraxis Bioscience LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.